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Abstract
Purpose of review There is an established association be-
tween hypertension and increased risk of poor cognitive per-
formance and dementia including Alzheimer’s disease; how-
ever, associations between antihypertensive medications
(AHMs) and dementia risk are less consistent. An increased
interest in AHM has resulted in expanding publications; how-
ever, none of the recent reviews are comprehensive. Our ex-
tensive review includes 15 observational and randomized con-
trolled trials (RCTs) published over the last 5 years, assessing
the relationship between AHM and cognitive impairment.
Recent findings All classes of AHM showed similar result
patterns in human studies with the majority of study results
reporting point estimates below one and only a small number
of studies (N = 15) reporting statistically significant results in
favor of a specific class.
Summary Only a small number of studies reported statistical-
ly significant results in favor of a specific class of AHM.
Methodological limitations of the studies prevent definitive
conclusions. Further work is now needed to evaluate the class
of AHM and cognitive outcomes in future RCTs, with a par-
ticular focus on the drugs with the promising results in both
animals and human observational studies.
Keywords Antihypertensivemedication .Cognitive decline .
Dementia . Alzheimer’s disease
Introduction
There is a long-established association between hypertension
and increased risk of age-related cognitive decline and demen-
tia [1], but the potential association between antihypertensive
treatment and reduced risk of dementia has been harder to
determine. The majority of observational studies, clinical tri-
als, and systematic reviews in this area suggest that antihyper-
tensive treatment may be associated with a decreased risk of
cognitive decline and incident dementia. However, the results
of individual studies vary widely; for example, one study
showed a 50 % reduction in incident dementia, while another
demonstrated no association between incident dementia and
any type of antihypertensive use [2–5].
Attempts to further understand the discrepancies in this
area have shifted attention towards the potential pleiotropic
effects of the different classes of antihypertensive medication
(AHM) and their potential impact on cognitive function [4, 5].
In 2009, two reviews were published on this topic. Fournier
et al. reported that calcium channel blocker (CCB) and angio-
tensin receptor blockers (ARBs) were the most promising
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antihypertensive classes with regard to prevention of incident
cognitive decline and dementia [5]. Shah et al. in another
review favored angiotensin-converting enzyme inhibitor
(ACE-I) and diuretics [4], although the numbers of constituent
studies were small, two for Alzheimer’s disease (AD), four for
vascular dementia, and five for any dementia outcomes [4].
Although publication in this area has expanded, none of the 16
more recent reviews (5 systematic and 11 non-systematic)
provide full oversight of the newer literature. Moreover, no
review to date has included a systematic update of the mech-
anistic animal and human studies, observational, and random-
ized controlled studies (RCTs) across the different classes of
AHM. This review aims to provide such an update in two
parts. Part 1 provides an overview of the recent human obser-
vational and clinical trial literature, and part 2 reviews the
recent physiological and animal work.
Methods
Search Strategy
The databases Embase, PsycINFO®, Medline, Medline in
process and other non-indexed citations, and PubMed were
searched from 2010 to February 2016 using the search terms
dementia or cognit* or mild cognitive impairment, and anti-
hypertensives, or antihypertensive agents, or diuretic or di-
uretics or thiazide-like or calcium channel blocker or calcium
channel blockers or calcium antagonist or angiotensin
converting enzyme inhibitor or angiotensin-converting en-
zyme inhibitors or ACE inhibitors or angiotensin receptor
blocker or angiotensin receptor blockers or ARB or beta
blocker or adrenergic beta-antagonists. Where review articles
were identified, reference lists were searched for original re-
search articles published within the last 5 years.
Inclusion and Exclusion Criteria
Included studies were required to be longitudinal, to report on
cognitive decline or incident dementia, and to exclude partic-
ipants with existing cognitive impairment. Studies reporting
solely on change in cognitive function scores were excluded.
Studies were required to include exposure to one of the anti-
hypertensive classes of interest, CCB, ARB, ACE-I, beta
blockers (BBs), and diuretics, and to have a control or com-
parator group.
Article Selection
Abstracts were double read and reviewed by RP and JP.
Discrepancies were resolved by discussion. Full text articles
were double read by the same team and data extracted into
standard tables, collated by antihypertensive class.
Quality Assessment
Quality was assessed against the key factors given in Critical
Appraisal Skills Program checklists [6] for evaluating trials
and longitudinal studies and a detailed table produced. A for-
mal scoring scheme was not used as this can lead to a loss of
subtlety when assessing quality.
Results
Searches retrieved 138 PubMed records and 522 records from
Medline, PsycINFO®, and Embase. Hand searching identified
two further articles. Seventeen full text articles were assessed
for eligibility [3, 7–13, 14•, 15–23]. Of these, three reported
solely on change in neuropsychological test score [7–9]; one
had no valid control group [10]; and in one, it was not clear
whether those with cognitive impairment at baseline had been
excluded [11] (see Figure A in supplemental material).
The 12 articles meeting the inclusion criteria reported on 14
studies (Table A in supplemental material). One article report-
ed the results for two randomized controlled trials, the
Ongoing Telmisartin Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET), and
Telmisartin Randomized Assessment Study in ACE
Intolerant Subjects with Cardiovascular Disease trial
(TRANSCEND) trials [3]. Five articles reported cohort stud-
ies [12, 13, 17–19], four from population-based samples [13,
17–19] and one from a clinical trial [12]. In the latter trial, the
data were treated as a cohort for the purposes of the analysis
since the clinical trial intervention had no impact on cognitive
function [12]. Three articles reported analyses of cohorts de-
rived retrospectively from medical record databases [16, 20,
21]; one was a systematic review but included unpublished
and relevant results from two further cohort studies [14•], and
two were case control analyses using records from existing
medical databases [15, 22].
The reporting of baseline characteristics varied widely.
However, all studies except one included both men and wom-
en, with the percentage women ranging from 2 to 3 % in the
studies using the US Veteran’s Affairs data [16, 21] to close to
50 % in the cohort studies [18–21]. One study only included
those with incident diabetes during the 4-year exposure period
[21], and the Honolulu Asia Aging Study (HAAS) included
only Japanese men who had previously participated in the
Honolulu Heart Program [17]. In addition to the HAAS, five
articles reported on data from the USA, the Cache County
study [19], the Ginkgo Evaluation and Memory Study
(GEMS) [12], and the 90+ study [14•], and two reported on
data from the US Veterans Affairs medical database [16, 21].
Other studies reported on Italian [18], UK [15], French [14•],
German [22], and Taiwanese [20] populations.
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The clinical trials recruited participants from 40 countries
around the world including sites in North and South America,
Europe, Asia and Australasia, and South Africa [3]. Study size
ranged from >800,000 assessed as part of the US Veterans
Affairs database [16] to 204 UK 85-year olds with 3-year
follow-up in the Newcastle 85+ study [13]. The majority of
the studies reported mean or median follow-up between 3 and
6 years [3, 12, 13, 16, 20, 22].
All studies reported on exposure to at least one of the AHM
classes under consideration, and most reported results for sev-
eral classes, although the percentage exposed by class differed
between studies, as described in Table B in the supplemental
material.
Outcome measures and comparator groups also varied with
results reported for incident AD [12, 15, 16, 19, 20], cognitive
impairment [3, 13, 17, 18], vascular dementia [15], and all-
cause dementia [14•, 15, 16, 21, 22]. The exposed samples
were compared to those taking other antihypertensive drugs
[3, 13, 14•, 15, 16, 18–20, 22], those not taking antihyperten-
sives [3, 12, 17], or both [19, 21].
CCBs
Six studies reported on CCBs [12, 13, 17, 19, 21, 22]
(Table 1). Five reported point estimates below one in favor
of CCB use reducing risk of cognitive decline or dementia
[12, 13, 17, 19, 21], but only two reached statistical signifi-
cance, the Newcastle 85+ study [13] and analyses of a cohort
from the US Veteran’s Affairs medical database [21]. In the
Newcastle 85+ study, CCB users compared to those taking
other antihypertensives were less likely to experience a drop
of four or more points in their Mini-Mental State Exam score.
However, the relationship was borderline when a drop of more
than the Reliable Change Index (RCI) was used instead [13].
The RCI is a means to calculate a measure of reliable change
in a cognitive test score. In the Veteran’s Affairs data, CCB
users were less likely to have a recorded diagnosis of dementia
[21]. No studies reported an increased risk associated with
CCB use.
ACE-I
Seven studies reported on ACE-I use [12, 13, 15, 17–19, 22]
(Table 2). Six reported point estimates below one in favor of
ACE-I use reducing risk of cognitive decline or dementia [12,
13, 15, 18, 19, 22], but only two reached statistical signifi-
cance, the GEMS study [12] and analyses of a cohort from the
UK General Practice Research Datalink medical database
(GPRD) [15]. The GEMS study reported a decreased risk of
AD compared to those not using antihypertensives [12],
whereas the GPRD data showed a reduced risk of probable
AD, possible AD, probable vascular dementia, Bunspecified
or other dementia,^ or Bany dementia^ in ACE-I users com-
pared to other antihypertensive use [15]. None of these studies
reported reductions in rates of cognitive decline. No studies
reported an increased risk associated with ACE-I use.
Table 1 Human studies reporting results related to calcium channel blocker (CCB) use
Author Study name Adjusted results
Yasar et al. 2013 [12] GEMS For incident Alzheimer’s disease—drug class vs non antihypertensive users
CCB HR 0.62 (0.35–1.09)
Gelber et al. 2013 [17] HAAS For incident cognitive impairment drug class vs non antihypertensive users
CCB alone IRR 0.97 (0.75–1.27)
Peters et al. 2015 [13] The Newcastle 85+ study For a fall in SMMSE of ≥4 points
CCB users compared to all other antihypertensive users OR 0.16 (0.03–0.79)
For a fall in SMMSE greater than reliable change index (Hensel et al. 2007)
CCB users compared to all other antihypertensive users OR 0.38 (0.15–1.00)
Chuang et al. 2014 [19] Cache County study For incident Alzheimer’s disease
CCB users compared to other antihypertensive users and non-users HR 0.75 (0.55–1.04)
Dihydropiridine CCB users compared to other antihypertensive users and non-users HR
0.75 (0.48–1.17)
Non-dihydropiridine CCB users compared to other antihypertensive users and non-users
HR 0.88 (0.60–1.30)
CCB users compared to other antihypertensive users HR 0.85 (0.60–1.20)
Dihydropiridine CCB users compared to other antihypertensive users HR 0.84 (0.53–
1.34)
Non-dihydropiridine CCB users compared to other antihypertensive users HR 0.99
(0.66–1.49)
Johnson et al. 2012 [21] Veterans Administration cohort For incident dementia drug class vs antihypertensive users and non-users
CCB HR 0.929 (0.893–0.966)
Wagner et al. 2012 [22] Disease Analyzer database cohort For incident dementia, antihypertensive drug type compared to matching control
CCB OR 1.10 (0.85–1.43)
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ARBs
Eight studies reported results for ARB use [3, 12, 15,
16, 20–22] (Table 3). Four reported point estimates be-
low one in favor of ARB use reducing risk of cognitive
decline or dementia [12, 15, 16, 21], and all reached
statistical significance. These included GEMS (AD)
[12] and three analyses of existing medical databases,
two using the US Veteran’s Affairs Database [21] and
reporting on AD and any dementia, and one the UK
GPRD database (AD, vascular, unspecified or other de-
mentia, or any dementia) [15]. The remaining four stud-
ies included the large multinational double-blind ran-
domized placebo-controlled trials, ONTARGET and
TRANSCEND comparing ARB use to ACE use or pla-
cebo, respectively [3], and analyses of existing medical
record databases in Taiwan [20] and Germany [22];
none of which found a relationship between ARB use
and mitigation of cognitive decline or risk for dementia.
Diuretics
Eight studies reported on diuretic use [12, 13, 14•, 17,
19, 21, 22] (Table 4). Seven reported point estimates
below one in favor of diuretic use reducing risk of
cognitive decline or dementia [12, 13, 14•, 19, 21,
22]; three reached statistical significance, GEMS (AD)
[12], the Cache County study (AD) [19], and analyses
of data from the US Veteran’s Affairs database
(dementia) [21]. Data from the 90+ and Three City
studies, as reported in the review by Tully et al., did
not reach significance [14•], and neither did analyses
from the Newcastle 85+ study [13] or those using the
German Disease Analyzer medical database [22]. The
HAAS reported a point estimate above one without sta-
tistical significance for the outcome of cognitive impair-
ment [17].
BBs
Six studies reported on BB use [12, 13, 17, 19, 21, 22]
(Table 5). Four reported point estimates in favor of BB
use reducing risk of cognitive impairment (HAAS) [17],
AD (GEMS) [12], and dementia (analyses from the US
Veteran’s Affairs and German Disease Analyzer medical
databases) [12, 22], respectively. In the Cache County
study, point estimates were below one for comparisons
of BB users to other antihypertensive users and non-
users combined but above one for comparisons to other
antihypertensive users alone. Neither comparison was
statistically significant [19]. In the Newcastle 85+ study,
the point estimate was also above one, suggesting the
Table 2 Human studies reporting results related to angiotensin-converting enzyme (ACE) inhibitor
Author Study name Adjusted results
Yasar et al. 2013 [12] GEMS For incident Alzheimer’s disease
Drug class vs non antihypertensive user ACE HR 0.50 (0.29–0.83)
Gelber et al. 2013 [17] HAAS For incident cognitive impairment drug class vs non antihypertensive users
ACE alone IRR 1.03 (0.71–1.50)
Solfrizzi et al. 2013 [18] ILSA For incident MCI
ACE compared to other antihypertensive medications HR 0.39 (0.12–1.24)
ACE compared to no antihypertensive medication HR 0.45 (0.16–1.28)
Peters et al. 2015 [13] The Newcastle 85+ study For a fall in SMMSE of ≥4 points
ACE users compared to all other antihypertensive users OR 0.41 (0.11–1.57)
For a fall in SMMSE greater than reliable change index (Hensel et al. 2007)
ACE users compared to all other antihypertensive users OR 0.71 (0.28–1.79)
Chuang et al. 2014 [19] Cache County study Whole sample, incident Alzheimer’s disease
ACE users compared to other antihypertensive users and non-users HR 0.95 (0.71–1.29)
Antihypertensive medication users, incident Alzheimer’s disease
ACE users compared to other antihypertensive users HR 1.06 (0.76–1.50)
Davies et al. 2014 [15] GPRD cohort ACE compared to other antihypertensive
Probable Alzheimer’s disease OR 0.76 (0.69–0.84)
Possible Alzheimer’s disease OR 0.80 (0.75–0.87)
Probable vascular dementia OR 0.82 (0.75–0.91)
Unspecified or other dementia OR 0.85 (0.75–0.96)
Any dementia OR 0.80 (0.76–0.84)
Wagner et al. 2012 [22] Disease Analyzer database cohort For incident dementia
Antihypertensive drug type compared to matching control
ACE OR 0.84 (0.65–1.08)
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potential for increased risk but without statistical signif-
icance [13].
Given the diversity of study designs, comparator groups, and
outcomes, it was not possible to meaningfully pool any results.
Quality Assessment, Human Observational, Cohort
Studies, and Trials
Multiple sources of bias are contained within the eligible stud-
ies. These include the differing designs, populations, compar-
ator groups, calculation of exposure to the antihypertensive
classes of interest, evaluation of outcome measures, and dif-
fering lengths of follow-up. See Tables C1–3 for details.
Discussion
The importance of dementia as a clinical and public
health issue is rapidly increasing as the population ages
[23]. Thus, identifying new and effective approaches to
prevention or treatment is critical. Due to the lengthy
process of developing new medications, there has been
Table 3 Human studies reporting results related to Angiotensin Receptor Blocker (ARB) use
Author Study name Adjusted results
Anderson et al. 2011 [3] ONTARGET Authors state that none of the treatment effects were changed appreciably when
adjusted sequentially with key variable.Anderson et al. 2011 [3] TRANSCEND
Yasar et al. 2013 [12] GEMS For incident Alzheimer's Disease - drug class vs non antihypertensive users
ARB HR 0.31(0.14-0.68)
Peters et al. 2015 [13] The Newcastle 85+ Study For a fall in SMMSE of >=4 points:
ARB users compared to all other antihypertensive users Numbers too small.
For a fall in SMMSE >reliable change index (Hensel et al. 2007):
ARB users compared to all other antihypertensive users Numbers too small
Li et al. 2010 [16] Veterans Affairs cohort 2002-2006 For the outcome of Alzheimer's Disease;
ARB compared to Lisinopril HR 0.81 (0.68-0.96)
ARB compared to CV comparator HR 0.84 (0.71-1.00)
For the outcome of dementia;
ARB compared to Lisinopril HR 0.81 (0.73-0.90)
ARB compared to CV comparator HR 0.76 (0.69-0.84)
Plus:
Those who switched from ACE to ARB during the study compared to those
who remained on ACE Results given for dementia: HR0.28 (0.24-0.32)
Combined ARB and ACE stronger results than ARB or ACE alone for both
dementia and Alzheimer's Disease outcomes.
Hsu et al. 2013 [20] Taiwan National Health Insurance cohort For incident Alzheimer's Disease:
All ARBs compared to non-ARB group HR 1.08 (0.96-1.22).
Johnson et al. 2012 [21] Veterans Affairs cohort 2002-2006 For incident dementia drug class vs antihypertensive users and non-users:
ARB HR 0.763 (0.699-0.834)
Davies et al. 2014 [15] GPRD cohort ARB compared to other antihypertensive
Probable Alzheimer's Disease OR 0.47 (0.37-0.58)
Possible Alzheimer's Disease OR 0.51 (0.43-0.61)
Probable Vascular Dementia OR 0.70 (0.57-0.85)
Unspecified or other dementia OR 0.62 (0.47-0.81)
Any dementia OR 0.55 (0.49-0.62)
Analysis of the association between years of defined daily dose exposure
suggests a stronger relationship between longer exposure to ACE and lower
OR for dementia, particularly Alzheimer’s disease. Relationship less clear
for ARBs.
Analysis of time lag data excluding 1,2....8 years of exposure prior to diagnosis
shows stronger relationship for exposure closer to index date for ACE and
probable or possible Alzheimer's Disease or probable vascular dementia.
Similar but much stronger patterns seen for ARBs and probable or possible
Alzheimer's Disease with ARB exposure associated with significantly lower
OR for all time lag periods.
Wagner et al. 2012 [22] Disease Analyzer Database cohort For incident dementia: Antihypertensive drug type compared to matching
control.
ARB OR 1.04 (0.66-1.64)
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a recent surge in interest towards re-purposing currently
available medications for the treatment of AD, including
AHM. In this paper, we provide an extensive review of
15 observational and randomized controlled studies pub-
lished over the last 5 years, assessing the relationship
between AHM and cognitive impairment.
Previous studies have shown a possible protective effect of
certain AHM against AD risk [1], and it has been suggested
that this protective effect is independent of, or in addition to,
the blood pressure-lowering effect [4, 5].
Six observational studies reported on CCB use as a group
and risk of cognitive decline or impairment [12, 13, 17, 19, 21,
22], but only two have reached statistical significance [13, 21].
However, no recent observational study has evaluated any
specific medications. This is most likely due to lack of power,
raising the need for either larger studies or meta-analysis of
multiple observational studies to provide information and
guidance for future RCTs.
Seven observational studies reported on ACE-I use [12, 13,
15, 17–19, 22], but only two studies reached statistical signif-
icance [12, 15]. Again, no observational study has evaluated
any specific medication, most likely due to lack of power. The
large multinational double-blind randomized placebo-
controlled trial ONTARGET compared the ACE-I ramipril
to the ARB telmisartan and found no significant difference
[3]. There was also no significant difference in a further large
multinational double-blind randomized placebo-controlled tri-
al, TRANSCEND, when comparing ARB (telmisartan) use to
placebo [3]. Overall, eight observational studies reported re-
sults for ARB use as a group [3, 12, 15, 16, 20–22], of which
four have reported risk reduction of cognitive decline or de-
mentia [12, 15, 16, 21].
There are eight observational studies reporting on diuretic
use [12, 13, 14•, 17, 19, 21, 22], with three reporting signifi-
cant risk reduction of cognitive decline or dementia [12, 19,
21]. Six observational studies reported on BB use [12, 13, 17,
Table 4 Human studies reporting results related to diuretic use
Author Study name Adjusted results
Yasar et al. 2013 [12] GEMS For incident Alzheimer’s disease drug class vs non antihypertensive users
Diuretics HR 0.51 (0.31–0.82)
Gelber et al. 2013 [17] HAAS For incident cognitive impairment drug class vs non antihypertensive users
Diuretic alone IRR 1.01 (0.75–1.38)
Peters et al. 2015 [13] The Newcastle 85+ study For a fall in SMMSE of ≥4 points
Thiazide and related diuretic users compared to all other antihypertensive users OR
0.70 (0.21–2.34)For a fall in SMMSE greater than reliable change index (Hensel
et al. 2007)
Thiazide and related diuretic users compared to all other antihypertensive users
OR 0.72 (0.28–1.86)
Chuang et al. 2014 [19] Cache County study For incident Alzheimer’s disease
Diuretic users compared to other antihypertensive users and non-users HR 0.72
(0.56–0.93)
Loop diuretic users compared to other antihypertensive users and non-users HR 0.98
(0.67–1.43)
Thiazide diuretic users compared to other antihypertensive users and non-users HR
0.70 (0.53–0.93)
Potassium sparing users compared to other antihypertensive users and non-users HR
0.69 (0.48–0.99)
For incident Alzheimer’s disease
Diuretic users compared to other antihypertensive users HR 0.77 (0.56–1.06)
Loop diuretic users compared to other antihypertensive users HR 1.09 (0.73–1.64)
Thiazide diuretic users compared to other antihypertensive users HR 0.75
(0.54–1.04)
Potassium sparing users compared to other antihypertensive users HR 0.74
(0.50–1.10)
Johnson et al. 2012 [21] Veterans Affairs cohort 2002–2006 For incident dementia drug class vs antihypertensive users and non users
Diuretics HR 0.864 (0.826–0.904)
Tully et al. 2016 [14•] Meta-analysis reporting unpublished
data from the 90+ study
For incident dementia
Diuretic use compared to control HR 0.90 (0.73–1.11)
Tully et al. 2016 [14•] Meta-analysis reporting unpublished
data from the Three Cities study
For incident dementia
Diuretic use compared to control HR 0.78 (0.38–1.59)
Wagner et al. 2012 [22] Disease Analyzer database cohort For incident dementia, antihypertensive drug type compared to matching control
Diuretics OR 0.89 (0.67–1.19)
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19, 21, 22], with four studies reporting risk reduction of cog-
nitive impairment [12, 17, 21, 22], respectively.
Previous animal studies and also RCTs with AHM have
shown that blood pressure reduction, particularly in close
proximity to development of cognitive impairment, does not
alter dementia risk. Thus, other mechanisms involved in AD
or dementia development should to be explored; however,
medications used in mechanistic studies have been different
agents to those used so far in RCTs.
Conclusions
All classes of AHM show similar patterns of results. The
majority of study results report point estimates below one,
and a small number of studies report statistically significant
results in favor of a specific class. The data is most mixed with
regard to ARBs, where four out of eight studies report signif-
icantly in favor of ARBs and four, including two double-blind
randomized controlled trials, report null results.
Inconsistencies in the sources of evidence, the use of hu-
man populations of differing ages, sex ratios, and prior or
concurrent exposure to AHM limit the possibility of drawing
firmer conclusions. Differing treatment times in studies,
methods for calculating exposure to treatment, outcome mea-
sures, and study designs with some studies potentially includ-
ing assessments during early, but as yet undiagnosed, demen-
tia also weaken the ability to draw conclusions. The relative
lack of information on blood pressure levels and use of differ-
ing covariates further serves to complicate interpretations.
These limitations restrict our ability to draw wider ranging
conclusions about use of specific antihypertensive classes,
subclasses, or individual drugs. Further work needs to include
cognitive outcomes such as early decline and select robust
covariates and comparator groups. In addition, future work
should explore key subgroups such as those with prior stroke
and cardiovascular disease, who are at higher risk for devel-
oping dementia. AHM that have had promising results in an-
imals and larger human observational studies are the specific
agents that should be selected for future RCTs.
Compliance with Ethical Standards
Conflict of Interest Dr. Ruth Peters reports grants from National
Institute of Health Research and from Imperial College, London. Drs.
Yasar Schuchman Jean Peters, Anstey, and Carlson declare no conflicts
of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of
blood pressure to cognitive function and dementia. Lancet Neurol.
2005;4:487–99.
Table 5 Human studies reporting results related to beta blocker (BB) use
Author Study name Adjusted results
Yasar et al. 2013 [12] GEMS For incident Alzheimer’s disease—drug class vs non antihypertensive users
BB HR 0.58 (0.36–0.93)
Gelber et al. 2013 [17] HAAS For incident cognitive impairment drug class vs non antihypertensive users
BB alone IRR 0.66 (0.48–0.94)
Peters et al. 2015 [13] The Newcastle 85+ study For a fall in SMMSE of ≥4 points
BB users compared to all other antihypertensive users OR 2.60 (0.96–7.07)
For a fall in SMMSE greater than reliable change index (Hensel et al. 2007)
BB users compared to all other antihypertensive users OR 1.68 (0.74–3.83)
Chuang et al. 2014 [19] Cache County study For incident Alzheimer’s disease
BB users compared to other antihypertensive users and non-users HR 0.90 (0.67–1.21)
BB users compared to other antihypertensive users HR 1.02 (0.73–1.43)
Johnson et al. 2012 [21] Veterans Affairs cohort 2002–2006 For incident dementia, drug class vs antihypertensive users and non-users
BB HR 0.956 (0.918–0.995)
Wagner et al. 2012 [22] Disease Analyzer database cohort For incident dementia, antihypertensive drug type compared to matching control
BB OR 0.79 (0.61–0.99)
Curr Hypertens Rep  (2016) 18:67 Page 7 of 8  67 
2. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH,
Babarskiene MR, et al. Prevention of dementia in randomized
double-blind placebo-controlled Systolic Hypertension in Europe
(Syst-Eur) trial. Lancet. 1998;352:1347–51.
3. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al.
ONTARGET and TRANSCEND Investigators. Renin-angiotensin
system blockade and cognitive function in patients at high risk of
cardiovascular disease: analysis of data from the ONTARGET and
TRANSCEND studies. Lancet Neurol. 2011;10(1):43–53.
4. Shah K, Qureshi S, JohnsonM, Parikh N, Schulz P, KunikM. Does
use of antihypertensive drugs affect the incidence or progression of
dementia? A systematic review. Am J GeriatrPharmacother.
2009;7:v250–61.
5. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achrd JM,
Faure S, et al. Prevention of dementia by antihypertensive drugs:
howAT1-receptor-blockers and dihydropyridines better prevent de-
mentia in hypertensive patients than thiazides and ACE-inhibitors.
Expert Rev Neurother. 2009;9:1413–31.
6. Critical appraisal skills programme checklists http://www.casp-uk.
net/#!checklists/cb36 accessed 06 May 2016.
7. Lovell MA, Abner E, Kryscio R, Xu L, Fister SX, Lynn BC.
Calcium channel blockers, progression to dementia, and effects
on amyloid beta peptide production. Oxid Med Cell Longev.
2015;2015:787805.
8. Paran E, Anson O, Lowenthal DT. Cognitive function and antihy-
pertensive treatment in the elderly: a 6-year follow-up study. Am J
Ther. 2010;17:358–64.
9. Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar
I. Modulation of renin-angiotensin system may slow conversion
from mild cognitive impairment to Alzheimer’s disease. J Am
Geriatr Soc. 2015;63:1749–56.
10. Hebert PL, McBean AM, O’Connor H, Frank B, Good C,
Maciejewski ML. Time until incident dementia among Medicare
beneficiaries using centrally acting or non-centrally acting ACE
inhibitors. Pharmacoepidemiol Drug Saf. 2013;22:641–8.
11. Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe DA. Long-
term effects of secondary prevention on cognitive function in stroke
patients. Circulation. 2013;128:1341–8.
12. Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, et al.
Antihypertensive drugs decrease risk of Alzheimer disease.
Neurology. 2013;81:896–903.
13. Peters R, Collerton J, Granic A, Davies K, Kirkwood T, Jagger C.
Antihypertensive drug use and risk of cognitive decline in the very
old: an observational study—the Newcastle 85+ study. J Hypertens.
2015;33:2156–64.
14.• Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive
drugs and incident dementia risk: a systematic review, meta-
analysis and meta-regression of prospective studies. J Hypertens.
2016;34:1027–35. Recent review focused on diuretic use.
15. Davies N, Kehoe P, Shlomo YB, Martin RM. Associations of
anti-hypertensive treatments with Alzheimer’s disease, vascu-
lar dementia, and other dementias. J Alzheimers Dis. 2014;26:
699–708.
16. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE,
et al. Use of angiotensin receptor blockers and risk of dementia in
a predominantly male population: a prospective cohort analysis.
BMJ. 2010;340:b5465.
17. Gelber R, Webster Ross G, Petrovitch H, Masaki KH, Launer LJ,
White L. Antihypertensive medication use and risk of cognitive
impairment. The Honolulu-Asia Aging Study Neurology.
2013;81:888–95.
18. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe P,
et al. Angiotensin-converting enzyme inhibitors and incidence of
mild cognitive impairment. The Italian Longitudinal Study on
Aging. Age. 2013;35:441–53.
19. Chuang YF, Breitner JCS, Chiu YL, Khachaturian A, Hayden K,
Corcoran C, et al. Use of diuretics is associated with reduced risk of
Alzheimer’s disease. The Cache County Study Neurobiol Aging.
2014;35:2429–35.
20. Hsu CY, Huang CC, Chan WL, Huang PH, Chiang CH, Chen TJ,
et al. Angiotensin-receptor blockers and risk of Alzheimer’s disease
in hypertension population—a nationwide cohort study. Circ J
Circulation Society. 2013;77:405–10.
21. Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chn H,
et al. Antihypertensive drug use and the risk of dementia in patients
with diabetes mellitus. Alzheimers Dement. 2012;8:437–44.
22. Wagner G, Icks A, Abholz HH, Schroder-Bernhardi D, Rathman W,
Kostev K. Antihypertensive treatment and risk of dementia: a retro-
spective database study. Int J ClinPharmacolTher. 2012;50:195–201.
23. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World
Alzheimer report 2015, The Global
 67 Page 8 of 8 Curr Hypertens Rep  (2016) 18:67 
